MarketPulse
A

$ALT

3 articles found
3 positive
0 negative
0 neutral
BenzingaBenzinga··Altimmune Inc

Altimmune Raises $225M in Oversubscribed Offering to Fuel Phase 3 MASH Trial

Altimmune closed a $225M oversubscribed public offering led by Deep Track Capital. Proceeds will fund Phase 3 MASH trial initiation in H2 2026 and operational runway through data readout.
ALTfinancingclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Altimmune Raises $225M in Oversubscribed Offering to Fund MASH Trial

Altimmune raises $225M in oversubscribed offering to fund Phase 3 MASH trial, pricing 64.25M shares at $3.00 each.
ALTwarrantspublic offering
BenzingaBenzinga··Equity-Insider.Com

Avaí Bio Advances Anti-Aging Therapy With Klotho Protein Cloning Milestone

Avaí Bio achieves critical Master Cell Bank milestone for α-Klotho protein therapy, partnering with Austrianova as cell therapy market surges toward $45B by 2035.
VRTXCRSPAVAIALTregenerative medicinegene therapy